USP35 is a Potential Immunosuppressive Factor in Skin Cutaneous Melanoma

References

• Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. Nat Commun. 2020;11(1):2858. doi:10.1038/s41467-020-15546-9
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Fischer GM, Jalali A, Kircher DA, et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 2019;9(5):628–645. doi:10.1158/2159-8290.CD-18-1489
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52(4):1071–1080. doi:10.3892/ijo.2018.4287
   PubMed Web of Science ®Google Scholar
• Namikawa K, Yamazaki N. Targeted therapy and immunotherapy for melanoma in Japan. Curr Treat Options Oncol. 2019;20(1):7. doi:10.1007/s11864-019-0607-8
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Candido S, Falzone L, et al. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 2020;57(3):609–618. doi:10.3892/ijo.2020.5088
   PubMed Web of Science ®Google Scholar
• Testori AAE, Ribero S, Indini A, et al. Adjuvant treatment of melanoma: recent developments and future perspectives. Am J Clin Dermatol. 2019;20(6):817–827. doi:10.1007/s40257-019-00456-4
   PubMed Web of Science ®Google Scholar
• Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191–5201. doi:10.1158/1078-0432.CCR-18-1550
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Veitia RA. A post-translational modification code for transcription factors: sorting through a sea of signals. Trends Cell Biol. 2009;19(5):189–197. doi:10.1016/j.tcb.2009.02.003
   PubMed Web of Science ®Google Scholar
• Sims RJ 3rd, Reinberg D. Is there a code embedded in proteins that is based on post-translational modifications? Nat Rev Mol Cell Biol. 2008;9(10):815–820. doi:10.1038/nrm2502
   PubMed Web of Science ®Google Scholar
• Deng L, Meng T, Chen L, et al. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11. doi:10.1038/s41392-020-0107-0
   PubMed Web of Science ®Google Scholar
• Ma J, Guo W, Li C. Ubiquitination in melanoma pathogenesis and treatment. Cancer Med. 2017;6(6):1362–1377. doi:10.1002/cam4.1069
   PubMed Web of Science ®Google Scholar
• Habel N, El-Hachem N, Soysouvanh F, et al. FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. Cell Death Differ. 2021;28(6):1837–1848. doi:10.1038/s41418-020-00710-x
   PubMed Web of Science ®Google Scholar
• Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle. 2009;8(11):1688–1697. doi:10.4161/cc.8.11.8739
   PubMed Web of Science ®Google Scholar
• Sarodaya N, Karapurkar J, Kim K-S, et al. The role of deubiquitinating enzymes in hematopoiesis and hematological malignancies. Cancers. 2020;12(5):5. doi:10.3390/cancers12051103
   Web of Science ®Google Scholar
• Schauer NJ, Magin RS, Liu X, et al. Advances in discovering deubiquitinating enzyme (DUB) inhibitors. J Med Chem. 2020;63(6):2731–2750. doi:10.1021/acs.jmedchem.9b01138
   PubMed Web of Science ®Google Scholar
• Scolyer RA, Rawson RV, Gershenwald JE, et al. Melanoma pathology reporting and staging. Mod Pathol. 2020;33(Suppl S1):15–24. doi:10.1038/s41379-019-0402-x
   PubMed Web of Science ®Google Scholar
• Kawada JI, Takeuchi S, Imai H, et al. Immune cell infiltration landscapes in pediatric acute myocarditis analyzed by CIBERSORT. J Cardiol. 2021;77(2):174–178. doi:10.1016/j.jjcc.2020.08.004
   PubMed Web of Science ®Google Scholar
• Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19(1):146. doi:10.1186/s12943-020-01262-x
   PubMed Web of Science ®Google Scholar
• Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11(7):556. doi:10.1038/s41419-020-02760-y
   PubMed Web of Science ®Google Scholar
• Fang Y, Shen X. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications. Cancer Metastasis Rev. 2017;36(4):669–682. doi:10.1007/s10555-017-9702-0
   PubMed Web of Science ®Google Scholar
• Jin WL, Mao XY, Qiu GZ. Targeting deubiquitinating enzymes in glioblastoma multiforme: expectations and challenges. Med Res Rev. 2017;37(3):627–661. doi:10.1002/med.21421
   PubMed Web of Science ®Google Scholar
• Li S, Zhang H, Wei X. Roles and mechanisms of deubiquitinases (DUBs) in breast cancer progression and targeted drug discovery. Life. 2021;11:9.
   Google Scholar
• Chen Z, Luo X, Lu Y, et al. Ubiquitination signals critical to regulatory T cell development and function. Int Immunopharmacol. 2013;16(3):348–352. doi:10.1016/j.intimp.2013.01.023
   PubMed Web of Science ®Google Scholar
• Hu H, Sun SC. Ubiquitin signaling in immune responses. Cell Res. 2016;26(4):457–483. doi:10.1038/cr.2016.40
   PubMed Web of Science ®Google Scholar
• Patrick RJ, Corey S, Glass LF. The use of sequential serial sectioning of thin melanomas in determining maximum Breslow depth. J Am Acad Dermatol. 2007;57(5 Suppl):S127–8. doi:10.1016/j.jaad.2006.02.007
   PubMed Web of Science ®Google Scholar
• Negin BP, Riedel E, Oliveria SA, et al. Symptoms and signs of primary melanoma: important indicators of Breslow depth. Cancer. 2003;98(2):344–348. doi:10.1002/cncr.11513
   PubMed Web of Science ®Google Scholar
• Djehal A, Krayem M, Najem A, et al. Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells. Eur J Med Chem. 2018;155:880–888. doi:10.1016/j.ejmech.2018.06.052
   PubMed Web of Science ®Google Scholar
• Chung YC, Hyun CG. Inhibitory effects of pinostilbene hydrate on melanogenesis in B16F10 melanoma cells via ERK and p38 signaling pathways. Int J Mol Sci. 2020;21(13):4732. doi:10.3390/ijms21134732
   PubMed Web of Science ®Google Scholar
• Aoki M, Fujishita T. Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153–189. doi:10.1007/82_2017_6
   PubMed Web of Science ®Google Scholar
• Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602–1609.
   PubMed Web of Science ®Google Scholar
• Xu Z, Han X, Ou D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2):575–587. doi:10.1007/s00253-019-10257-8
   PubMed Web of Science ®Google Scholar
• Liu XR, Wang W, Li HM. KLHL22 promotes malignant melanoma growth in vitro and in vivo by activating the PI3K/Akt/mTOR signaling pathway. Neoplasma. 2020;67(5):1106–1113. doi:10.4149/neo_2020_190923N954
   PubMed Web of Science ®Google Scholar
• Chamcheu JC, Roy T, Uddin M, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8(8):803. doi:10.3390/cells8080803
   PubMed Web of Science ®Google Scholar
• Lee N, Zakka LR, Mihm MC, et al. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48(2):177–187. doi:10.1016/j.pathol.2015.12.006
   PubMed Web of Science ®Google Scholar
• Schatton T, Scolyer RA, Thompson JF, et al. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287–324.
   PubMedGoogle Scholar
• Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869–875. doi:10.1200/JCO.2006.08.9755
   PubMed Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689–713. doi:10.1007/s00018-017-2686-7
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Raskov H, Orhan A, Christensen JP, et al. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–367. doi:10.1038/s41416-020-01048-4
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhao J, Zhang W, et al. Aberrant alternative splicing in breast cancer. J Mol Cell Biol. 2019;11(10):920–929. doi:10.1093/jmcb/mjz033
   PubMed Web of Science ®Google Scholar
• Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21(35):5400–5413. doi:10.1038/sj.onc.1205651
   PubMed Web of Science ®Google Scholar